Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness

Clinica Chimica Acta

Volumn 406, Issue 1-2, 2009, Pages 129-133

  Dullaart, Robin P F ^a   Plomgaard, Peter ^b   de Vries, Rindert ^a   Dahlbäck, Björn ^c   Nielsen, Lars B ^b,d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Apolipoprotein M; Intima media thickness; Leptin; Metabolic syndrome

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN M; CHOLESTEROL; GLUCOSE; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN;

ADULT; ARTERIAL WALL THICKNESS; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; OBESITY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPONECTIN; ANALYSIS OF VARIANCE; APOLIPOPROTEINS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEPTIN; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RESISTIN; TUNICA INTIMA;

EID: 67650251213     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.06.010     Document Type: Article

References (33)

1. Xu N., and Dahlbäck B. A novel human apolipoprotein (apoM). J Biol Chem 274 (1999) 31286-31290
2. Dahlbäck B., and Nielsen L.B. Apolipoprotein M affecting lipid metabolism or just catching a ride with lipoproteins in the circulation?. Cell Mol Life Sci 66 (2009) 559-564
3. Nielsen L.B., Christoffersen C., Ahnström J., and Dahlbäck B. ApoM: gene regulation and effects on HDL metabolism. Trends Endocrinol Metab 20 (2009) 66-71
4. Wolfrum C., Poy M.N., and Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 11 (2005) 418-422
5. Christoffersen C., Jauhiainen M., Moser M., et al. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem 283 (2008) 1839-1847
6. Wolfrum C., Howell J., Ndungo E., and Stoffel M. Foxa2 activity increases plasma HDL levels by regulating apolipoprotein M. J Biol Chem 283 (2008) 16940-16942
7. Faber K., Axler O., Dahlback B., and Nielsen L.B. Characterization of apoM in normal and genetically modified mice. J Lipid Res 45 (2004) 1272-1278
8. Zhang X., Jiang B., Luo G., Nilsson-Ehle P., and Xu N. Hyperglycemia down-regulates apolipoprotein M expression in vivo and in vitro. Biochim Biophys Acta 1771 (2007) 879-882
9. Xu N., Nilsson-Ehle P., Hurtig M., and Ahren B. Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo. Biochem Biophys Res Commun 321 (2004) 916-921
10. Xu N., Nilsson-Ehle P., and Ahren B. Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects. J Nutr Biochem 15 (2004) 579-582
11. Ahnstrom J., Axler O., Jauhiainen M., et al. Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. J Lipid Res 49 (2008) 1912-1917
12. Plomgaard P, Dullaart RPF, de Vries R, Groen AK, Dahlbäck B, Nielsen LB. Apolipoprotein M predicts pre-ß-HDL formation: studies in type 2 diabetic and nondiabetic subjects. J Intern Med in press. doi:10.111-j.1365/2796/2009.02095.X.
13. Axler O., Ahnstrom J., and Dahlback B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res 48 (2007) 1772-1780
14. Fielding C.J., and Fielding P.E. Molecular physiology of reverse cholesterol transport. J Lipid Res 36 (1995) 211-228
15. Borggreve S.E., de Vries R., and Dullaart R.P.F. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 33 (2003) 1051-1069
16. O'Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., and Wolfon S.K. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. N Engl J Med 340 (1999) 14-22
17. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
18. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
19. Selzer R.H., Hodis H.N., Kwong-Fu H., et al. Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images. Atherosclerosis 111 (1994) 1-11
20. van Himbergen T.M., Roest M., de Graaf J., et al. Indications that paraoxonase-1 contributes to high density lipoprotein levels in familial hypercholesterolemia. J Lipid Res 46 (2005) 445-451
21. Liu M.Y., Xydakis A.M., Hoogeveen R.C., et al. Multiplexed analysis of biomarkers and the metabolic syndrome in human plasma, using the Luminex-100 system. Clin Chem 51 (2005) 1102-1109
22. Klamer A., Skogstrand K., Hougaard D.M., Nørgaard-Petersen B., Juul A., and Greisen G. Adiponectin levels measured in dried blood spot samples from neonates born small and appropriate for gestational age. Eur J Endocrinol 157 (2007) 189-194
23. Tzou W.S., Douglas P.S., Srinivasan S.R., et al. Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J Am Coll Cardiol 46 (2005) 457-463
24. Ahluwalia N., Drouet L., Ruidavets J.-B., et al. Metabolic syndrome is associated with markers of subclinical atherosclerosis in a French population-based sample. Atherosclerosis 186 (2006) 345-353
25. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28 (2005) 2745-2749
26. Mantzoros C.S., Moschos S., Avramopoulos I., et al. Leptin concentrations in relation to body mass index and the tumor necrosis factor-alpha system in humans. J Clin Endocrinol Metab 82 (1997) 3408-3413
27. Kern P.A., Di Gregorio G.B., Lu T., Rassouli N., and Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 52 (2003) 1779-1785
28. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 189 (2006) 47-60
29. Luo G., Hurtig M., Zhang X., Nilsson-Ehle P., and Xu N. Leptin inhibits apolipoprotein M transcription and secretion in human hepatoma cell line, HepG2 cells. Biochimica Biophys Acta 734 (2005) 198-202
30. Christoffersen C., Ahnstrom J., Axler O., Christensen E.I., Dahlback B., and Nielsen L.B. The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma. J Biol Chem 283 (2008) 18765-18772
31. Mackness M., Durrington P., and Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol 15 (2004) 399-404
32. Dullaart R.P.F., de Vries R., Sluiter W.J., and Voorbij H.A. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus. Clin Endocrinol 70 (2009) 221-226
33. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 107 (2003) 391-397